VEEV vs. WAT: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at VEEV and WAT, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | VEEV | WAT |
|---|---|---|
| Company Name | Veeva Systems Inc. | Waters Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Technology | Life Sciences Tools & Services |
| Market Capitalization | 49.47 billion USD | 19.50 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | October 16, 2013 | November 17, 1995 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of VEEV and WAT by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | VEEV | WAT |
|---|---|---|
| 5-Day Price Return | 0.34% | 1.78% |
| 13-Week Price Return | 6.13% | -6.17% |
| 26-Week Price Return | 36.26% | -5.06% |
| 52-Week Price Return | 49.55% | -6.36% |
| Month-to-Date Return | 1.31% | 9.29% |
| Year-to-Date Return | 43.54% | -11.68% |
| 10-Day Avg. Volume | 1.45M | 0.64M |
| 3-Month Avg. Volume | 1.37M | 0.74M |
| 3-Month Volatility | 27.81% | 43.63% |
| Beta | 1.04 | 1.17 |
Profitability
Return on Equity (TTM)
VEEV
13.40%
Health Care Technology Industry
- Max
- 48.09%
- Q3
- 41.80%
- Median
- 18.17%
- Q1
- 11.64%
- Min
- 11.05%
VEEV’s Return on Equity of 13.40% is on par with the norm for the Health Care Technology industry, indicating its profitability relative to shareholder equity is typical for the sector.
WAT
35.02%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.51%
- Median
- 6.47%
- Q1
- 3.86%
- Min
- -6.95%
WAT’s Return on Equity of 35.02% is exceptionally high, placing it well beyond the typical range for the Life Sciences Tools & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
VEEV
27.29%
Health Care Technology Industry
- Max
- 52.24%
- Q3
- 49.15%
- Median
- 33.59%
- Q1
- 16.86%
- Min
- 13.38%
VEEV’s Net Profit Margin of 27.29% is aligned with the median group of its peers in the Health Care Technology industry. This indicates its ability to convert revenue into profit is typical for the sector.
WAT
21.71%
Life Sciences Tools & Services Industry
- Max
- 32.18%
- Q3
- 18.30%
- Median
- 10.19%
- Q1
- 4.20%
- Min
- -2.05%
A Net Profit Margin of 21.71% places WAT in the upper quartile for the Life Sciences Tools & Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
VEEV
26.93%
Health Care Technology Industry
- Max
- 74.05%
- Q3
- 65.56%
- Median
- 33.50%
- Q1
- 22.83%
- Min
- 21.46%
VEEV’s Operating Profit Margin of 26.93% is around the midpoint for the Health Care Technology industry, indicating that its efficiency in managing core business operations is typical for the sector.
WAT
27.69%
Life Sciences Tools & Services Industry
- Max
- 38.39%
- Q3
- 21.40%
- Median
- 13.57%
- Q1
- 8.38%
- Min
- -3.51%
An Operating Profit Margin of 27.69% places WAT in the upper quartile for the Life Sciences Tools & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | VEEV | WAT |
|---|---|---|
| Return on Equity (TTM) | 13.40% | 35.02% |
| Return on Assets (TTM) | 10.96% | 14.40% |
| Net Profit Margin (TTM) | 27.29% | 21.71% |
| Operating Profit Margin (TTM) | 26.93% | 27.69% |
| Gross Profit Margin (TTM) | 75.59% | 59.02% |
Financial Strength
Current Ratio (MRQ)
VEEV
5.57
Health Care Technology Industry
- Max
- 6.49
- Q3
- 6.49
- Median
- 6.02
- Q1
- 3.62
- Min
- 2.96
VEEV’s Current Ratio of 5.57 aligns with the median group of the Health Care Technology industry, indicating that its short-term liquidity is in line with its sector peers.
WAT
1.75
Life Sciences Tools & Services Industry
- Max
- 3.46
- Q3
- 2.78
- Median
- 1.91
- Q1
- 1.53
- Min
- 0.43
WAT’s Current Ratio of 1.75 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
VEEV
0.00
Health Care Technology Industry
- Max
- 0.14
- Q3
- 0.10
- Median
- 0.01
- Q1
- 0.00
- Min
- 0.00
Falling into the lower quartile for the Health Care Technology industry, VEEV’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
WAT
0.67
Life Sciences Tools & Services Industry
- Max
- 1.35
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
WAT’s Debt-to-Equity Ratio of 0.67 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
VEEV
169.00
Health Care Technology Industry
- Max
- 224.12
- Q3
- 224.12
- Median
- 219.00
- Q1
- 219.00
- Min
- 219.00
VEEV’s Interest Coverage Ratio of 169.00 is below the typical range for the Health Care Technology industry. This suggests a weaker ability to meet debt obligations compared to its peers and may indicate a higher level of financial risk.
WAT
11.29
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
WAT’s Interest Coverage Ratio of 11.29 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | VEEV | WAT |
|---|---|---|
| Current Ratio (MRQ) | 5.57 | 1.75 |
| Quick Ratio (MRQ) | 5.48 | 1.22 |
| Debt-to-Equity Ratio (MRQ) | 0.00 | 0.67 |
| Interest Coverage Ratio (TTM) | 169.00 | 11.29 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
VEEV
0.00%
Health Care Technology Industry
- Max
- 0.89%
- Q3
- 0.70%
- Median
- 0.15%
- Q1
- 0.04%
- Min
- 0.00%
VEEV currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
WAT
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.41%
- Q3
- 0.65%
- Median
- 0.35%
- Q1
- 0.00%
- Min
- 0.00%
WAT currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
VEEV
0.00%
Health Care Technology Industry
- Max
- 101.92%
- Q3
- 87.10%
- Median
- 42.63%
- Q1
- 10.66%
- Min
- 0.00%
VEEV has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
WAT
0.00%
Life Sciences Tools & Services Industry
- Max
- 113.14%
- Q3
- 61.34%
- Median
- 17.74%
- Q1
- 0.00%
- Min
- 0.00%
WAT has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | VEEV | WAT |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
VEEV
61.18
Health Care Technology Industry
- Max
- 280.41
- Q3
- 225.12
- Median
- 59.01
- Q1
- 44.08
- Min
- 39.20
VEEV’s P/E Ratio of 61.18 is within the middle range for the Health Care Technology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
WAT
28.89
Life Sciences Tools & Services Industry
- Max
- 75.35
- Q3
- 51.00
- Median
- 32.93
- Q1
- 25.27
- Min
- 1.43
WAT’s P/E Ratio of 28.89 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
VEEV
16.69
Health Care Technology Industry
- Max
- 146.49
- Q3
- 115.78
- Median
- 19.83
- Q1
- 7.94
- Min
- 5.25
VEEV’s P/S Ratio of 16.69 aligns with the market consensus for the Health Care Technology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
WAT
6.27
Life Sciences Tools & Services Industry
- Max
- 10.49
- Q3
- 6.43
- Median
- 4.66
- Q1
- 2.88
- Min
- 1.08
WAT’s P/S Ratio of 6.27 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
VEEV
7.00
Health Care Technology Industry
- Max
- 115.01
- Q3
- 89.07
- Median
- 9.11
- Q1
- 4.04
- Min
- 3.06
VEEV’s P/B Ratio of 7.00 is within the conventional range for the Health Care Technology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
WAT
9.62
Life Sciences Tools & Services Industry
- Max
- 6.69
- Q3
- 5.00
- Median
- 3.46
- Q1
- 2.38
- Min
- 0.93
At 9.62, WAT’s P/B Ratio is at an extreme premium to the Life Sciences Tools & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | VEEV | WAT |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 61.18 | 28.89 |
| Price-to-Sales Ratio (TTM) | 16.69 | 6.27 |
| Price-to-Book Ratio (MRQ) | 7.00 | 9.62 |
| Price-to-Free Cash Flow Ratio (TTM) | 37.31 | 30.85 |